Pacira Faces Two Shareholder Suits Seeking To Block Viatris' $36.50 Cash Buyout
Pacira and its board plan to defend their merger disclosures, while shareholders have sent 15 demand letters.
Pacira BioSciences, which develops and sells non-opioid pain treatments, faces two shareholder lawsuits seeking to stop Viatris' $36.50-per-share offer until additional merger information is released. Viatris described the challenges in a tender-offer amendment filed Thursday, alongside 15 disclosure demand letters received by Pacira.
Disclosure Claims Target The Buyout
The suits, Carroll v. Pacira BioSciences and Burke v. Pacira BioSciences, were filed by purported shareholders in New York state Supreme Court in New York County. They name Pacira and every member of its board as defendants.
The plaintiffs allege that Pacira's response to the tender offer left out or misrepresented important merger information. Their claims include negligent misrepresentation, concealment and negligence under New York common law.
They seek court orders preventing the transaction from closing until the allegedly missing information is supplied. If the deal closes, they want it unwound or actual and punitive damages, along with legal and expert fees and expenses.
Pacira's 15 demand letters include two draft complaints and generally request further information. Pacira and its board intend to contest the actions and believe their disclosures meet applicable law. Viatris said it cannot predict the outcome or estimate possible losses.
Halper Sadeh, a law firm examining the sale, announced an investigation into potential securities-law violations or breaches of fiduciary duties.
Cash Offer Near The Share Price
Viatris and Pacira signed the merger agreement on October 8, and the buyer filed its tender offer on Friday, October 30. Viatris is offering cash for all outstanding Pacira shares, with applicable withholding taxes deducted and no interest paid.
PCRX shares stood at $36.46 at Thursday's close, close to the $36.50 offered to holders. Pacira's market value was $1.5 billion at Thursday's close.
The Brisbane, California-based company sells three commercial products. EXPAREL is a long-acting local anesthetic injection approved for postsurgical pain; ZILRETTA is an extended-release steroid injection for osteoarthritis knee pain. Its handheld iovera device targets nerves with cold to relieve pain without drugs.
EXPAREL generated $575.1 million in sales in 2025, accounting for 79% of total revenue. ZILRETTA sales were $116.6 million, while iovera sales were $24.2 million. Pacira is also developing PCRX-201, a gene therapy in mid-stage trials for knee osteoarthritis.
S&P Dow Jones Indices scheduled Pacira's SmallCap 600 removal before trading opens Tuesday, with Ingram Micro replacing it.
Sources
- SC TO-T/A — Viatris Inc re: Pacira BioSciences, Inc. (PCRX) — SEC EDGAR
- Ingram Micro Holding Set to Join S&P SmallCap 600 - Nov 11, 2026 — press.spglobal.com
- Are BWIN, CCC, PCRX Obtaining Fair Deals for their Shareholders? — prnewswire.com